Amgen AMGN

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. 10 Healthcare Dividend Dogs Tap 6% To 13% July Upsides

      Headlines

      Wed, 9 Jul 2014

      By Fredrik Arnold : Yield ( dividend / price) results from here verified by Yahoo Finance for small, mid, & large cap Healthcare stocks as of market closing prices as of July 7 compared with analyst 1-yr target projections led to five actionable conclusions discussed below. Small cap firms were ...

    2. Bind Therapeutics ends cancer drug partnership with Amgen

      Headlines

      Wed, 2 Jul 2014

      July 2 (Reuters) - Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

    3. Bind and Amgen complete research program

      Headlines

      Wed, 2 Jul 2014

      Therapeutics ( BIND -3.4% ) and Amgen ( AMGN +0.6% ) notify each other that ..... develop an Accurin incorporating the Amgen therapeutic payload. The collaboration ..... and programmable nanomedicines and Amgen 's undisclosed proprietary cancer

    4. BTD for Amgen's blinatumomab

      Headlines

      Tue, 1 Jul 2014

      The FDA designates Amgen 's ( AMGN ) investigational bispecific T cell engager ( BiTE ) antibody blinatumomab a Breakthrough Therapy for adults with Philadelphia

    5. Amgen Inc. Bonds: A Rare Combination Of Low Risk And High Value

      Headlines

      Mon, 30 Jun 2014

      By Donald van Deventer : Amgen Inc. ( AMGN ) seeks to unlock the potential of ..... the U.S. dollar bonds issued by Amgen Inc. and compare its current default ..... on 11 fixed-rate bond issues of Amgen Inc., with June 27 trading volume

    6. New Morningstar Analyst Report for Celgene Corp

      Stock Reports

      Thu, 26 Jun 2014

      and is vying with Revlimid in the first-line setting, and Amgen 's Kyprolis launched as a second-line option in 2012.The ..... multiple myeloma, and this drug--as well as new drugs such as Amgen 's Kyprolis--could limit Revlimid's growth potential

    7. New Morningstar Analyst Report for Teva Pharmaceutical Industries Ltd

      Stock Reports

      Tue, 24 Jun 2014

      Teva’s position could weaken considerably if peers, such as strong partnerships between Baxter and Momenta or Actavis and Amgen , can achieve bioequivalent and interchangeable approvals with original innovator products. Like other branded drug companies

    8. From Barron’s, June 23, 2014 (Part 2)

      Commentary

      Sat, 21 Jun 2014

      investorsentimentreadings.html Bullish stories: Auto-parts supplier Magna International [ MGA ; pg 14]; 6 dividend-growth stocks [ AMGN , ETN, GE, IP, JPM, NOV ; pg 15]; energy E&P company Apache [ APA ; pg 17]; Pier 1 [ PIR ; selloff on missed Q1 overdone

    9. Top Holdings of Four All-Weather Ultimate Stock-Pickers

      Headlines

      Tue, 17 Jun 2014

      Market Cap ($ Mil.) % Stock Holdings Buying/ Selling Biogen BIIB 2 Wide 309.78 1.26 Medium 73,257 7.8 ( - ) Amgen AMGN 4 Wide 116.2 0.89 Medium 87,966 5 ( - ) Roche Hldg RHHBY 2 Wide 37.37 1.07 Low 255,874 4.4 + Eli Lilly

    10. 6 Healthcare Dividend Dogs Dope 10% To 44% June Upsides

      Headlines

      Sun, 15 Jun 2014

      By Fredrik Arnold : Yield ( dividend /price) results from here verified by Yahoo Finance for small, mid, and large cap Healthcare stocks as of market closing prices as of June 12 compared with analyst 1-yr target projections led to four actionable conclusions discussed below. Small cap firms were

    « Prev12345Next »
    Content Partners